Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight
FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.
Could nonthermal tumor ablation replace surgery for low-risk thyroid cancer? Pulse Biosciences launches feasibility study
Pulse Biosciences begins human study of nsPFA thyroid cancer treatment. Discover what this trial could mean for minimally invasive oncology.
Could Io Therapeutics’ IRX4204 reshape the science of breast cancer prevention?
Could IRX4204 help prevent triple-negative breast cancer? Discover what new RXR agonist research could mean for the future of breast cancer prevention.
Proton therapy delivers survival gain in head and neck cancer: Could this Lancet trial shift payer and policy resistance?
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the […]